Clinical Trials Logo

Cardiomyopathies clinical trials

View clinical trials related to Cardiomyopathies.

Filter by:

NCT ID: NCT03726424 Recruiting - Clinical trials for Hypertrophic Cardiomyopathy

Outcome of Different Pathogenic Mutations in Hypertrophic Cardiomyopathy

Start date: February 25, 2011
Phase:
Study type: Observational

This is a prospective, single-center study to assess clinical phenotype and prognosis of different pathogenic mutations in Chinese patients with hypertrophic cardiomyopathy. Patients with hypertrophic cardiomyopathy were consecutively recruited, and then DNA samples were extracted from peripheral blood. Targeted sequencing of 142 genes was performed to obtain variants associated with hypertrophic cardiomyopathy. Patients will undergo face-to-face interviews, phone calls, or/and chart reviews at 6 months, 12 months, 24 months, 36 months, 48 months and 60 months for data collection of clinical outcomes.

NCT ID: NCT03723655 Enrolling by invitation - Clinical trials for Hypertrophic Cardiomyopathy

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

Start date: October 5, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Approximately 35 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study. Note: Up to 100 sites in the US, Europe, and Israel who participate in EXPLORER-HCM (Study MYK-461-005) will be added when the study design is updated to include enrollment of participants from that study.

NCT ID: NCT03719040 Not yet recruiting - Heart Failure Clinical Trials

His Bundle Pacing Registry

Start date: December 31, 2018
Phase:
Study type: Observational [Patient Registry]

The His Bundle Pacing registry is a prospective, observational, multi-center registry performed to gain a broader understanding of 1) the His bundle pacing (HBP) device implant and follow-up workflows, including device and programmer measurements and 2) the clinical utility in creating a 3-dimensional electro-anatomical map of the His bundle prior to device implants based on the clinical site's routine care.

NCT ID: NCT03706001 Not yet recruiting - Depression Clinical Trials

Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression

Start date: October 20, 2018
Phase: N/A
Study type: Interventional

A Study to evaluate the efficacy of psychotherapy for easing the cardiac symptoms and improving and quality of life in patients with hypertrophic cardiomyopathy accompanied with depression

NCT ID: NCT03705312 Not yet recruiting - Heart Failure Clinical Trials

MitraClip for the Treatment of Moderate Functional Mitral Regurgitation: EVOLVE-MR

EVOLVE-MR
Start date: October 2018
Phase: N/A
Study type: Interventional

This study evaluates the addition of transcatheter mitral valve repair with the MitraClip device to medical treatment in patients with heart failure and moderate functional mitral regurgitation to determine the impact of left ventricular remodelling and patients' functional capacity.

NCT ID: NCT03704701 Recruiting - Clinical trials for Cardiovascular Diseases

The Interrogation of the Cardiomyopathy of Chronic Kidney Disease With advancEd caRdiac Imaging

TICKER
Start date: October 10, 2018
Phase:
Study type: Observational

Patients with kidney failure have a much higher risk of heart disease compared to people of the same age without kidney failure. The reason for this is not fully understood. In this project we will use Cardiac MRI (CMR), which is a very detailed scan of the heart and blood vessels, to try to better understand the cardiovascular changes that occur in kidney failure. We will perform CMR scans in 30 patients before and after dialysis (a treatment for patients with kidney failure) to see whether dialysis changes the heart muscle. The same patients will also undergo another type of heart scan, called a CT scan. This will allow us to compare the pictures from the 2 different types of scan to help us better understand any damage to the heart muscle that is present. Finally, we will test a new way to measure hardening of blood vessels on CMR. These three studies will help us to better understand the heart and blood vessel changes that happen in kidney failure. This research will also be useful for patients without kidney failure. We hope to be able to use it in the future to see which new treatments might be able to reduce the risk of heart disease in patients with kidney failure.

NCT ID: NCT03702829 Not yet recruiting - Amyloidosis Clinical Trials

24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients

Start date: December 2018
Phase: Phase 2
Study type: Interventional

Transthyretin is a protein produced in the liver that transports thyroid hormone and vitamin A. A single substitution of an amino acid in the structure of TTR can result in a relatively unstable protein, the breakdown products of which (predominantly monomers) aggregate abnormally and produce proteinaceous deposits in nerves and the heart. These deposits are known as amyloid and produce progressive nerve and heart damage. Amyloidosis due to a mutant TTR is usually an autosomal dominant and hence is a familial condition. Wild-type TTR is also capable of producing amyloid deposits which predominantly involves the heart (rather than the nervous system) resulting in a progressive decrease in cardiac function with increasing signs of heart failure. This study aims to determine whether subcutaneous injection of an antisense oligonucleotide drug, known as inotersen, that has been specifically designed to reduce production of the protein transthyretin by the liver, can slow or stop the progression of TTR amyloid cardiomyopathy as compared to historical controls, using advanced echocardiography and cardiac MRI. The study also aims to determine the tolerability and safety of this drug when administered over a 24-month period to patients with TTR amyloid cardiomyopathy.

NCT ID: NCT03696628 Recruiting - Clinical trials for Cardiomyopathy, Familial

Modeling and Pharmacological Targeting of Genetic Cardiomyopathy in Children Via Cardiomyocytes Derived From Induced Pluripotent Stem Cells (DMDstem)

DMDstem
Start date: September 25, 2017
Phase: N/A
Study type: Interventional

Interventional, cross-sectional biomedical study of children with genetic cardiomyopathy and healthy children. The aim is to generate, via induced human pluripotent stem cells (hiPSC), "patient-specific" cardiomyocytes (CMs) (hiPSC-CMs) to study the molecular mechanisms of cardiomyopathies of genetic origin.

NCT ID: NCT03685149 Not yet recruiting - Clinical trials for Arrhythmogenic Right Ventricular Cardiomyopathy

Pilot Randomized Trial With Flecainide in ARVC Patients

Start date: January 2019
Phase: Phase 2
Study type: Interventional

Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) is an inherited arrhythmia disorder with high risk of ventricular tachycardia or fibrillation, and implantable cardioverter defibrillator remains as therapy of choice. Antiarrhythmic therapy with different agents including beta-blockers, sotalol and amiodarone are usually not effective in reducing risk of arrhythmic events. Recent data indicated that flecainide effectively prevented the arrhythmias observed in the experimental ARVC animals and in small series of ARVC patients. These observations provide a strong rationale for conducting a pilot randomized clinical trial to determine whether flecainide will reduce ventricular arrhythmias in high-risk ARVC patients. This pilot study is designed as randomized double-blinded placebo-controlled crossover trial with administration of 100 mg of Flecainide or matching placebo twice a day for 4 weeks each with a washout period. Primary specific aim of this pilot trial is to determine whether Flecainide administration is associated with a significant reduction of number of ventricular ectopic beats (VEBs) in ARVC patients with implantable cardioverter-defibrillator (ICD).

NCT ID: NCT03663348 Recruiting - Clinical trials for Takotsubo Cardiomyopathy

Registry of Patients With Takotsubo Syndrome

Start date: September 11, 2009
Phase:
Study type: Observational [Patient Registry]

Takotsubo syndrome is a condition which mimics acute myocardial infarction, and is diagnosed in 1.5% to 2.2% of patients referred to hospital with suspected acute coronary syndrome. It is also known as broken heart syndrome, takotsubo cardiomyopathy, stress cardiomyopathy and apical ballooning cardiomyopathy, among other names. The pathogenesis of this disorder is not well understood. Possible mechanisms include catecholamine excess, coronary artery spasm, microvascular dysfunction, among others. This is a multicenter, nation-wide, observational study of patients who were previously diagnosed with takotsubo syndrome. The investigators aim to use this registry to help plan and carry out further studies and to improve understanding of the pathophysiologic mechanisms of this syndrome. In addition participants will be followed for events, and to monitor quality of life and stress.